Most of what is written about GLP-1 medicines treats the reader as a generic patient. Yet the majority of people taking them are women, and several of the effects that matter most are ones only women experience.
Your cycle can change. Fertility can return after years of assuming it had gone. One of these medicines interferes with the contraceptive pill and another does not. And the tissue you lose alongside the fat is the same tissue menopause is already taking.
None of this is an argument against taking them. It is the information that should come with them, and often does not.
The names overlap confusingly, so it helps to separate them.
Semaglutide acts on one receptor. Tirzepatide acts on two, and produces greater weight loss. That difference matters more than the branding suggests, and it becomes important below.
Women report irregular timing, heavier or lighter bleeding, missed periods and spotting. These are real, though they were not systematically recorded in the original trials.
The mechanism is mostly indirect. Substantial weight loss changes the signalling between brain and ovaries, and fat tissue itself produces oestrogen, so losing a lot of it shifts your hormonal picture. Rapid fat loss may also release oestrogen that was stored in that tissue, which is one proposed explanation for unexpected bleeding.
One reassurance from the data. A pharmacovigilance analysis of more than 100,000 reports from women found gynaecological bleeding events in 0.60 per cent of tirzepatide cases and 0.62 per cent of semaglutide cases, with no meaningful difference between them. Bleeding changes are reported, but not at a rate that singles out either drug.
What still warrants a call to your doctor rather than a forum: bleeding after menopause, bleeding that is unusually heavy or prolonged, or periods that stop entirely. Heavy or erratic periods covers what is normal in the transition and what is not.
The phenomenon has a nickname, which tells you how common it has become. An "Ozempic baby" is an unexpected pregnancy in a woman who had assumed she could not conceive.
The mechanism is straightforward once stated. Excess weight and insulin resistance suppress ovulation. Remove enough of both and ovulation returns, sometimes after years of infertility.
The trial evidence in PCOS is striking. In a study of 100 women with PCOS and irregular cycles, adding semaglutide to metformin for 16 weeks restored regular cycles in 73 per cent, against 42 per cent on metformin alone. Natural pregnancy rates in the months afterwards were 35 per cent against 15 per cent. Another study found roughly 80 per cent of women with PCOS who responded to low-dose semaglutide normalised their cycles.
Those numbers are excellent news for a woman trying to conceive. They are a problem for a woman who is not, and who has been treating infertility as her contraception.
PCOS explained covers the underlying condition, and trying to conceive over 35 covers the fertility side.
This is the most important paragraph on this page, because the two drugs behave differently and the distinction is not obvious from the packaging.
Tirzepatide reduces the effectiveness of the contraceptive pill. Its manufacturer's own pharmacology data show oral contraceptive hormone exposure falling by roughly 20 per cent after a single 5 mg dose, with larger reductions after dose increases. The delayed stomach emptying that makes you feel full also slows absorption of the pill. The label advises switching to a non-oral method, or adding a barrier method, for four weeks after starting and for four weeks after every dose increase.
Semaglutide does not show this effect. Its prescribing information reports no clinically relevant interaction with oral contraceptives.
Non-oral methods are unaffected by either. The coil, implant, injection, patch and vaginal ring do not pass through the stomach, so nothing here applies to them.
Put the two findings together and the risk becomes clear. A woman on tirzepatide may have ovulation returning at the same time as her pill is working less well, during exactly the weeks when her dose is being increased. That combination is how surprises happen.
Hormonal and non-hormonal contraception covers the alternatives.
These medicines are not approved for use in pregnancy, and animal studies show potential harm to the foetus. Semaglutide's label instructs stopping at least two months before a planned pregnancy.
Human data are thin. One cohort of 168 first-trimester exposures found no increase in major birth defects or pregnancy loss, which is encouraging but far too small to settle the question.
If a pregnancy happens unexpectedly while you are taking one, that is a conversation with your doctor rather than a cause for panic. Do not stop any prescribed medicine on your own.
Here is where the menopause context changes the calculation, and where most coverage of these drugs is silent.
You lose muscle alongside fat. All rapid weight loss costs lean tissue, and these medicines produce rapid weight loss. In a woman of twenty-five that is recoverable. In a woman of fifty-two it lands on top of the muscle loss already underway as oestrogen falls.
Our article on losing weight in menopause makes the case at length: the goal in midlife is losing fat while keeping muscle, because muscle is what keeps your energy requirement up, your bones loaded and your metabolism steady. A drug that suppresses appetite makes it easy to eat too little protein at precisely the point you need more.
Bone density is the second concern. Weight loss reduces bone density in anyone, and postmenopausal women are already losing bone rapidly. The combination deserves attention rather than assumption. Protecting your bones covers what actually helps.
Neither is a reason not to take these medicines. Both are reasons to take them differently from a thirty-year-old.
Two things protect you, and they are the same two things that work without the drug:
Hair shedding occurs in roughly 2 per cent of women, and more often after rapid loss. It is usually telogen effluvium, the temporary shedding that follows any physiological stress, and it typically recovers. Thinning hair and hormones covers the difference between shedding and pattern loss.
Facial volume loss, the thing the internet calls "Ozempic face", is not a drug effect. It is what substantial fat loss does to a face at any age, and it is more visible in women who have less facial fat to begin with.
Taste and smell changes come up frequently in patient reports, including a metallic taste and heightened sensitivity to odours.
If you are a woman of reproductive age, or in perimenopause and still cycling:
"Which drug am I on, and does it affect my contraception?" If the answer is tirzepatide and you take the pill, you need a backup method during initiation and every dose increase.
"Could my fertility return?" If you have PCOS or a history of infertility linked to weight, assume yes and plan accordingly.
"How will we protect my muscle?" A good answer includes a protein target and resistance training. An answer that only discusses the scales is incomplete.
"Should my bone density be checked?" Particularly if you are postmenopausal or have other risk factors.
"What happens when I stop?" Weight regain after stopping is common and well documented. A plan that ends when the prescription does is not a plan.
These medicines work, and they work well. For women carrying weight that has resisted everything else, particularly with PCOS or insulin resistance, they can change the trajectory of their health in a way nothing else has.
What they are not is a treatment that behaves identically in a woman of thirty-five and a woman of fifty-five. The cycle effects, the fertility return, the contraceptive interaction and the muscle question are all specific to female physiology, and they are largely absent from the conversation.
Knowing them does not make the decision harder. It makes it yours.
Can GLP-1 medications affect my periods?
Yes. Irregular timing, changes in flow and missed periods are commonly reported, driven mainly by substantial weight loss shifting the signalling between brain and ovaries rather than by the drug acting directly on your reproductive system.
Do GLP-1 medications affect the contraceptive pill?
Tirzepatide does. Its label advises a non-oral or barrier method for four weeks after starting and after each dose increase. Semaglutide has not shown a clinically relevant interaction. Coils, implants, injections, patches and rings are unaffected by either.
What is an "Ozempic baby"?
An unexpected pregnancy in a woman taking a GLP-1 medicine, usually after years of infertility linked to weight or PCOS. Weight loss restores ovulation, and with tirzepatide reduced pill absorption can compound it.
Should I stop before trying to conceive?
Yes. These medicines are not approved in pregnancy and semaglutide's label instructs stopping at least two months before a planned pregnancy. Discuss the timing with your doctor rather than stopping on your own.
Will I lose muscle?
Some, as with any rapid weight loss. It matters more in midlife because oestrogen decline is already costing you muscle. Eating enough protein and lifting weights twice a week are the two things that protect it.
Do they help PCOS?
Used off-label, yes. In one study adding semaglutide to metformin restored regular cycles in 73 per cent of women against 42 per cent on metformin alone, alongside improvements in insulin resistance.
What happens to my weight if I stop?
Regain is common and well documented. This is why the muscle and training side matters: what you keep afterwards depends heavily on what you built while taking it.
Sources: Eli Lilly, MOUNJARO (tirzepatide) US prescribing information, sections 7.1 and 12.3, oral contraceptive interaction · Novo Nordisk, OZEMPIC (semaglutide) US prescribing information, section 7.2, revised October 2025 · Jastreboff AM et al., Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), N Engl J Med 2022;387:205-16 · Wilding JPH et al., Once-weekly semaglutide in adults with overweight or obesity (STEP 1), N Engl J Med 2021;384:989-1002 · FDA Adverse Event Reporting System pharmacovigilance analysis of gynaecological haemorrhage, tirzepatide versus semaglutide, 2022-2025 · Bauer J et al., Evidence-based recommendations for optimal dietary protein intake in older people, J Am Med Dir Assoc 2013;14:542-59 · Educational only, not medical advice. Never stop or change a prescribed medicine without speaking to your doctor.
Keep reading: Losing weight in menopause · PCOS explained · Why lifting is best for midlife hormones · Protecting your bones · Contraception, compared · Take the free Hormone Quiz